LOXL2 and idiopathic pulmonary fibrosis: There are several potential novel therapeutic strategies for MF coming from the idiopathic pulmonary fibrosis armamentarium (Transforming growth factor beta inhibitor pirfenidone; tyrosine kinase inhibitor nintedanib; pamrevlumab, a human monoclonal antibody that inhibits connective tissue growth factoractivity; simtuzumab, a humanized monoclonal antibody to block lysyl oxidase like 2), some of them showing promising results in preliminary studies (7).